
---
title: '印度开发新型狂犬病疫苗：只需打3针'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://picsum.photos/400/300?random=9031'
author: 科学网
comments: false
date: Thu, 21 Jul 2022 11:55:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=9031'
---

<div>   
<p style="line-height: 150%"><strong><span style="font-family: SimSun;line-height: 150%;color: #2E495E;font-size: 29px"><span style="font-family:SimSun">印度开发新型狂犬病疫苗：只需打</span><span style="font-family:Cambria-Bold">3</span><span style="font-family:SimSun">针</span><a name="OLE_LINK1" href="http://blog.sciencenet.cn/undefined"></a></span></strong></p><p style="text-indent: 42px;line-height: 150%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 150%;color: #069A2E;letter-spacing: 0;font-size: 21px">虽然目前印度的人口总数在世界上还只占第二位（发展趋势是很快就会超越中国），但印度每年的狂犬病发病人数却多年雄踞世界第一位，常常超过两万人。近几年印度的狂犬病防治工作进步很快，全国已出现了一些基本消除了狗引发的人狂犬病的先进地区；在狂犬病相关的科研和疫苗生产方面也成绩斐然。以下简介印度新近研究出的一种新型狂犬病疫苗，作暴露后预防只需打</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 150%;color: #069A2E;letter-spacing: 0;font-size: 21px">3针而不是常规的打5针。</span></strong></p><p style="text-indent: 42px;line-height: 150%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 150%;color: #069A2E;letter-spacing: 0;font-size: 21px">相关论文于今年一月发表（见文末的参考文献）。</span></strong></p><p style="margin-left: 0;text-indent: 51px;line-height: 150%"><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 24px">摘要</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 150%"><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">狂犬病是一种可以用疫苗预防的疾病。然而，对</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">狂犬病</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">疫苗</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">全程接种</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">的依从性仅为</span>40%。因此，</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">迫切</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">需要</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">有</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">一种安全、具有免疫原性、</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">疗程</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">较短的疫苗，以增强依从性并有效预防该病。为此，采用</span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">病毒样颗粒技术</span>(Virus-Like Particle technology, VLP)</span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">研制了一种新型</span>3剂量重组纳米颗粒狂犬病G蛋白疫苗，提高了疫苗的免疫原性和安全性。疫苗剂量的减少导致</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">就</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">诊次数和旅费的减少</span>;以及增加</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">依从性</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">，这对预防狂犬病很重要。</span></p><p style="margin-left: 0;text-indent: 45px;line-height: 150%"><strong><span style="font-family: Cambria-Bold;line-height: 150%;color: #231F20;font-size: 21px">关键词</span></strong><strong><span style="font-family: Cambria-Bold;line-height: 150%;color: #231F20;font-size: 21px">:</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"> Rabies</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">（狂犬病）</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">; Recombinant Rabies G Protein</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">（</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">重组狂犬病</span>G蛋白</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">）</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">; VL</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">P（病毒样颗粒） </span></p><p style="margin-left: 0;text-indent: 51px;line-height: 150%"><strong><span style="font-family: MinionPro-Bold;line-height: 150%;color: #8F133A;font-size: 24px">前言</span></strong></p><p style="margin-top:0;margin-right:4px;margin-bottom:0;margin-left:0;text-indent:43px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:150%"><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">狂犬病是一种由</span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">狂犬病毒</span>(RABV)</span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">引起的人畜共患病毒性疾病，在所有传染病中病死率最高。狂犬病</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">目前</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">在</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">全球</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">100多个国家和地区</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">存在</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">。为预防狂犬病，及时和</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">完整</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">的</span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">暴露</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">后预防</span>(PEP)</span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">是必要的。目前，狂犬病疫苗</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">接种的经典程序是</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">在第</span>0、3、7、14和28天</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">共</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">接种</span>5剂，但研究表明，完成整个疗程的依从性只有40%。因此，解决这些</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">局限性</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">的有效方法是减少人注射</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">PEP</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">的</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">总</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">剂量，并且需要一种通过加速</span>PEP</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">程序以</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">改善免疫结果的新</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">型</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">疫苗。为此，印度艾哈迈达巴德</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">（</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">Ahmedabad</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">）的</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei';line-height: 150%;color: #2A2B2E;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:Microsoft YaHei">卡迪拉</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">（</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">Cadila</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">）</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">制药有限公司</span></span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">开发了一种新型重组纳米颗粒型狂犬病</span>G蛋白疫苗</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"> (</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">Thrabis</span></strong><span style=";font-family:Calibri;line-height:150%;color:#231F20;font-size:20px">®</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">)</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">，该疫苗采用</span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">病毒样颗粒</span>(VLP)</span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">技术制备。</span></p><p style="margin-left: 0;text-indent: 51px;line-height: 150%"><strong><span style="font-family: Cambria-Bold;line-height: 150%;color: #231F20;font-size: 24px"><span style="font-family:Cambria-Bold">重组纳米颗粒狂犬病</span>G蛋白疫苗</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 150%"><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">利用</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">VLP</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">平台制备</span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">重组狂犬病</span>G蛋白疫苗</span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">，是</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">选择编码狂犬病</span>G蛋白的基因序列</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">，</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">然后将这些基因克隆到杆状病毒中，使杆状病毒感染</span><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">昆虫细胞</span>(</span></span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">sf9</span></span></strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">)</span></span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">。目的抗原</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">在</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">sf9</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">细胞中表达</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">，</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">通过多种色谱技术</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">进行纯化</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">。纯化的靶抗原以多肽的形式存在，该多肽在亚基抗原的多个拷贝中以</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">定向且</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">有序阵列的方式存在。这可能会模拟自然宿主</span>-病原体表面相互作用的重复性、几何形状、大小和形状。这种纳米颗粒提供了多个结合位点的集合强度(avidity)，并能提供更好的抗原稳定性和免疫原性。安全性是</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">VLPs</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">的</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">一个主要</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">优</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">点</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">。与传统疫苗一样，</span><a name="OLE_LINK4" href="http://blog.sciencenet.cn/undefined"></a>VLPs<span style="font-family:Cambria">具有免疫原性，在控制传染病方面效果显著。</span></span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">VLPs</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">不能复制、重组或</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">发生</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">重</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">配</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">，因为它们不包含有</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">感</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">染性的</span>DNA或RNA物质;因此，</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">VLPs</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">比传统疫苗更安全。与化学合成的产品相比，</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">VLPs</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">也</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">具有若干优势，如尺寸更小</span>(10 - 2000纳米)、可获得其结构的高分辨率</span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">三维</span>(3D)</span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">模型、构造灵活、高产率以及每种类型</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">的</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">病毒或</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">VLP</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">的结构</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">一致</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">性。</span></p><p style="margin-left: 0;text-indent: 51px;line-height: 150%"><strong><span style="font-family: Cambria-Bold;line-height: 150%;color: #231F20;font-size: 24px">临床研究</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 150%"><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">一项多中心、标签</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">开放</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">、评</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">审</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">者盲、中心特定区</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">段</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">随机、平行设计的</span>III期临床研究在800名受试者中进行。符合条件的受试者按2:1的比例随机分为重组狂犬病G蛋白疫苗</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">组</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">和对照疫苗</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">组</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">。重组狂犬病</span>G蛋白疫苗组在第0、3、7天接种3剂疫苗;而</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">对照</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">疫苗组的受试者在第</span>0、3、7、14和28天接种了5剂经世卫组织资格预</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">认证</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">的疫苗。主要目的是证明试验疫苗在第一次注射后</span>14天相对于</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">对照</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">疫苗在血清保护率</span>(RVNA</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">即狂犬病毒中和抗体</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">滴度</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">≥</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">0.5IU/mL)方面的非劣效性。次要终点是第一剂研究疫苗接种后42天的血清保护率，以及在0天和</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">180</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">天之间</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">主动和被动</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">报告</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">的</span><strong><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">不良事件</span>(AEs</span></span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">)的频率</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">。在</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"> <span style="font-family:Cambria">第</span>14天，试验疫苗组99.24%血清阳性，</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">对照</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">疫苗组</span>97.72%血清阳性;差异在统计学上无显著性。同样，在第42天，试验疫苗组中98.69%的受试者血清阳性，</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">对照</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">疫苗组中</span>100.00%的受试者血清阳性，差异无统计学意义。与试验组相比，</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">对照</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">组出现</span><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px"><span style="font-family:Cambria">不良事件</span>(AEs)</span></span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"><span style="font-family:Cambria">的参与者数量显著增加</span>(17.2% </span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">对</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">9.9%， P=0.0032)。所有的</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">AEs</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">性质为轻度至中度，</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">都自行缓解而</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">无任何并发症。最常见的局部</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">AEs</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">是注射部位的疼痛</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">和</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">红肿。全身</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">AEs</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">为发热、头痛、耳痛、荨麻疹、关节痛、恶心。</span></p><p style="margin-left: 0;text-indent: 51px;line-height: 150%"><strong><span style="font-family: MinionPro-Bold;line-height: 150%;color: #8F133A;font-size: 24px">结论</span></strong></p><p style="margin-left:0;text-indent:43px;text-autospace:ideograph-numeric;line-height:150%"><span style=";font-family:Calibri;line-height:150%;font-size:20px"><span style="font-family:Calibri">新型</span><span style="font-family:Calibri">3剂量重组狂犬病G蛋白疫苗</span></span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px"> (</span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 20px">Thrabis</span></strong><span style=";font-family:Calibri;line-height:150%;color:#231F20;font-size:20px">®</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:20px">)</span><span style=";font-family:Calibri;line-height:150%;font-size:20px"><span style="font-family:Calibri">是安全的，具有免疫原性，在模拟暴露后预防中可与</span><span style="font-family:Calibri">5剂经过了世卫组织资格预认证的疫苗相媲美。疫苗剂量的减少导致就诊次数和旅费的减少;同时可增加依从性，这对预防狂犬病很重要，并最终有助于到2030年消除犬类介导的人类狂犬病。</span></span></p><p style="text-autospace:ideograph-numeric;line-height:150%"><strong><span style="font-family: Calibri;line-height: 150%;font-size: 21px">参考文献：</span></strong></p><p style="line-height: 150%;"><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:19px">Agrawal Ashok, et al.,  </span><strong><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 19px">A Novel 3 Dose Rabies Vaccine</span></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:19px">. </span><strong><em><span style="font-family: Cambria;line-height: 150%;color: #231F20;font-size: 19px">Biomed J Sci & Tech Res</span></em></strong><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:19px"> 41(2)-2022. BJSTR. MS.ID.006574.</span><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:19px"> </span><a href="https://biomedres.us/pdfs/BJSTR.MS.ID.006574.pdf" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Cambria;line-height: 150%;color: #0000FF;font-size: 19px">https://biomedres.us/pdfs/BJSTR.MS.ID.006574.pdf</span></span></a><span style=";font-family:Cambria;line-height:150%;color:#231F20;font-size:19px"> </span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-347754-1348222.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-347754-1348222.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1347851.html" target="_black">狂犬病暴露后预防（PEP）会失败吗？(4)</a><br>                    <!--大赛结束-->
                                        
  
</div>
            